Why the study?
Does increased use of beta-blockers improve clinical outcomes and cost-effectiveness in survivors of myocardial infarction?
Does increased use of beta-blockers improve clinical outcomes and cost-effectiveness in survivors of myocardial infarction?
Increased use of beta-blockers after MI in eligible patients would lead to substantial gains in health and is highly cost-effective or potentially cost-saving.
No takes yet. Share an insight, caveat, or question.
Highly cost-effective in post-MI modeling; leaves open prospective validation in contemporary cohorts.
Kathryn A. Phillips (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: